Abstract
Background: The therapeutic properties of cannabinoids are well-known since ancient years. Growing evidence exist on endocannabinoid system (ECS) modulation related with human tumorigenesis.
Objective: Taking into account the substantial role of ECS on immune cell regulation, the present review is aimed to summarize the emerging evidence concerning cannabinoid receptor (CBR) expression and cannabinoid ligand effects on haematological malignancies.
Conclusions: Most of cannabinoid actions, mainly CB2R-mediated against haematopoietic malignant cells, seem promising, as inhibition of cell proliferation and apoptosis and paraptosis induction have been documented. Cannabinoid ligands appear to activate rudimentary pathways for cell survival, such as ERK, JNK, p38 MAPK, and to induce caspase synthesis, in vitro. Such data are strongly recommended to be confirmed by in vivo experiments with emphasis on cannabinoid ligands’ bioavailability and phytocannabinoid psychotropic properties. The preliminary antitumoral ECS effects and their relative lack of important side effects render ECS a promising therapeutic target for the treatment of haematological malignancies.
Keywords: Cannabinoids, Cannabinoid receptors, Endocannabinoid system, Haematological malignancies, Leukemia, Lymphoma.
Current Medicinal Chemistry
Title:Endocannabinoid System: A Promising Therapeutic Target for the Treatment of Haematological Malignancies?
Volume: 23 Issue: 22
Author(s): Constantinos Giaginis, Eleftheria Lakiotaki, Penelope Korkolopoulou, Konstantinos Konstantopoulos, Efstratios Patsouris and Stamatios Theocharis
Affiliation:
Keywords: Cannabinoids, Cannabinoid receptors, Endocannabinoid system, Haematological malignancies, Leukemia, Lymphoma.
Abstract: Background: The therapeutic properties of cannabinoids are well-known since ancient years. Growing evidence exist on endocannabinoid system (ECS) modulation related with human tumorigenesis.
Objective: Taking into account the substantial role of ECS on immune cell regulation, the present review is aimed to summarize the emerging evidence concerning cannabinoid receptor (CBR) expression and cannabinoid ligand effects on haematological malignancies.
Conclusions: Most of cannabinoid actions, mainly CB2R-mediated against haematopoietic malignant cells, seem promising, as inhibition of cell proliferation and apoptosis and paraptosis induction have been documented. Cannabinoid ligands appear to activate rudimentary pathways for cell survival, such as ERK, JNK, p38 MAPK, and to induce caspase synthesis, in vitro. Such data are strongly recommended to be confirmed by in vivo experiments with emphasis on cannabinoid ligands’ bioavailability and phytocannabinoid psychotropic properties. The preliminary antitumoral ECS effects and their relative lack of important side effects render ECS a promising therapeutic target for the treatment of haematological malignancies.
Export Options
About this article
Cite this article as:
Giaginis Constantinos, Lakiotaki Eleftheria, Korkolopoulou Penelope, Konstantopoulos Konstantinos, Patsouris Efstratios and Theocharis Stamatios, Endocannabinoid System: A Promising Therapeutic Target for the Treatment of Haematological Malignancies?, Current Medicinal Chemistry 2016; 23 (22) . https://dx.doi.org/10.2174/0929867323666160530144934
DOI https://dx.doi.org/10.2174/0929867323666160530144934 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
“Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews Serum miRNAs Signature Plays an Important Role in Keloid Disease
Current Molecular Medicine Is there Any Correlation Between Binding and Functional Effects at the Translocator Protein (TSPO) (18 kDa)?
Current Molecular Medicine Xanthones as Potential Antioxidants
Current Medicinal Chemistry Copper Compounds in Cancer Chemotherapy
Current Medicinal Chemistry Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Estrogen Regulation of MicroRNA Expression
Current Genomics Iron Oxide Nanoparticle Platform for Biomedical Applications
Current Medicinal Chemistry A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry MicroRNA Therapeutics: The Emerging Anticancer Strategies
Recent Patents on Anti-Cancer Drug Discovery Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism A Role of Immunotherapy in Metastatic Malignant Melanoma
Central Nervous System Agents in Medicinal Chemistry Cyclization in Opioid Peptides
Current Drug Targets Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Regulation of Apoptosis and Cell Survival by Resveratrol
Mini-Reviews in Organic Chemistry Curcumin: A Promising Agent Targeting Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Advances in Cancer Stem Cell Therapy: Targets and Treatments
Recent Patents on Regenerative Medicine Oncolytic Viruses Driven by Tumor-Specific Promoters
Current Cancer Drug Targets Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry